AR073748A1 - Anticuerpos anti-cxcr4 y su utilizacion para el tratamiento del cancer - Google Patents
Anticuerpos anti-cxcr4 y su utilizacion para el tratamiento del cancerInfo
- Publication number
- AR073748A1 AR073748A1 ARP090103802A ARP090103802A AR073748A1 AR 073748 A1 AR073748 A1 AR 073748A1 AR P090103802 A ARP090103802 A AR P090103802A AR P090103802 A ARP090103802 A AR P090103802A AR 073748 A1 AR073748 A1 AR 073748A1
- Authority
- AR
- Argentina
- Prior art keywords
- cxcr4
- antibodies
- cancer treatment
- inducing
- activation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 5
- 230000004913 activation Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13677208P | 2008-10-01 | 2008-10-01 | |
| EP08305631A EP2172485A1 (en) | 2008-10-01 | 2008-10-01 | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| US17374309P | 2009-04-29 | 2009-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073748A1 true AR073748A1 (es) | 2010-12-01 |
Family
ID=40361774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103802A AR073748A1 (es) | 2008-10-01 | 2009-10-01 | Anticuerpos anti-cxcr4 y su utilizacion para el tratamiento del cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8557964B2 (enExample) |
| EP (2) | EP2172485A1 (enExample) |
| JP (1) | JP5723279B2 (enExample) |
| KR (1) | KR101671039B1 (enExample) |
| CN (1) | CN102209730B (enExample) |
| AR (1) | AR073748A1 (enExample) |
| AU (1) | AU2009299787B2 (enExample) |
| BR (1) | BRPI0920531A2 (enExample) |
| CA (1) | CA2738782C (enExample) |
| CL (1) | CL2011000730A1 (enExample) |
| CY (1) | CY1115572T1 (enExample) |
| DK (1) | DK2342233T3 (enExample) |
| ES (1) | ES2503732T3 (enExample) |
| GE (1) | GEP20146084B (enExample) |
| HR (1) | HRP20140899T1 (enExample) |
| IL (1) | IL212066A (enExample) |
| MA (1) | MA32928B1 (enExample) |
| MX (1) | MX2011003509A (enExample) |
| NZ (1) | NZ592363A (enExample) |
| PL (1) | PL2342233T3 (enExample) |
| PT (1) | PT2342233E (enExample) |
| RS (1) | RS53578B1 (enExample) |
| RU (1) | RU2573897C2 (enExample) |
| SI (1) | SI2342233T1 (enExample) |
| TW (1) | TWI469792B (enExample) |
| UA (1) | UA102867C2 (enExample) |
| WO (1) | WO2010037831A1 (enExample) |
| ZA (1) | ZA201102969B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| AU2011322508A1 (en) * | 2010-10-27 | 2013-05-02 | Pierre Fabre Medicament | Antibodies for the treatment of HIV |
| US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| AR087364A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| NL2010658C2 (en) * | 2013-04-18 | 2014-10-21 | Bosch Gmbh Robert | Thermostat for a hvac. |
| MY190252A (en) | 2013-08-02 | 2022-04-08 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates |
| AU2014324102B2 (en) * | 2013-09-23 | 2021-01-28 | Wilson Wolf Manufacturing, LLC | Improved methods of genetically modifying animal cells |
| TWI740824B (zh) * | 2015-04-27 | 2021-10-01 | 法商皮爾法伯製藥公司 | 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一） |
| CN108026173A (zh) | 2015-06-12 | 2018-05-11 | 百时美施贵宝公司 | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 |
| JP7452829B2 (ja) * | 2015-11-09 | 2024-03-19 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのエピトープおよびそれに対する抗体 |
| CN108350052A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中间区域中的表位及其构象选择性抗体 |
| WO2017132202A1 (en) | 2016-01-25 | 2017-08-03 | Nant Holdings Ip, Llc | Nk cells with altered cxcl12/cxcr4 signaling |
| WO2017203799A1 (ja) * | 2016-05-25 | 2017-11-30 | 株式会社東芝 | エネルギー管理装置、管理システム、消費電力監視方法及びプログラム |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CN110234352A (zh) * | 2017-01-31 | 2019-09-13 | Msm蛋白质技术公司 | 抗cxcr4抗体 |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| US20230181635A1 (en) | 2018-03-13 | 2023-06-15 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| CN110804100A (zh) * | 2019-11-01 | 2020-02-18 | 中国人民解放军陆军特色医学中心 | 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN112661845B (zh) * | 2020-12-25 | 2022-06-21 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及其应用 |
| CN112521500B (zh) * | 2020-12-25 | 2022-06-24 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及应用 |
| WO2025049591A1 (en) * | 2023-08-28 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Anti-cxcr4 antibodies and uses thereof |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| US9029097B2 (en) * | 2005-02-16 | 2015-05-12 | Universite De Montreal | Biosensors for monitoring receptor-mediated G-protein activation |
| EP1871807B1 (en) * | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| MX2010012435A (es) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anticuerpos anti-cxcr4. |
-
2008
- 2008-10-01 EP EP08305631A patent/EP2172485A1/en not_active Withdrawn
-
2009
- 2009-09-30 TW TW98133164A patent/TWI469792B/zh not_active IP Right Cessation
- 2009-10-01 GE GEAP200912211A patent/GEP20146084B/en unknown
- 2009-10-01 PL PL09744645T patent/PL2342233T3/pl unknown
- 2009-10-01 DK DK09744645.4T patent/DK2342233T3/da active
- 2009-10-01 UA UAA201105412A patent/UA102867C2/uk unknown
- 2009-10-01 CN CN200980144491.4A patent/CN102209730B/zh not_active Expired - Fee Related
- 2009-10-01 MX MX2011003509A patent/MX2011003509A/es active IP Right Grant
- 2009-10-01 CA CA2738782A patent/CA2738782C/en not_active Expired - Fee Related
- 2009-10-01 ES ES09744645.4T patent/ES2503732T3/es active Active
- 2009-10-01 AU AU2009299787A patent/AU2009299787B2/en not_active Ceased
- 2009-10-01 RS RSP20140515 patent/RS53578B1/sr unknown
- 2009-10-01 BR BRPI0920531-4A patent/BRPI0920531A2/pt not_active IP Right Cessation
- 2009-10-01 PT PT97446454T patent/PT2342233E/pt unknown
- 2009-10-01 JP JP2011529559A patent/JP5723279B2/ja not_active Expired - Fee Related
- 2009-10-01 HR HRP20140899AT patent/HRP20140899T1/hr unknown
- 2009-10-01 AR ARP090103802A patent/AR073748A1/es unknown
- 2009-10-01 KR KR1020117009556A patent/KR101671039B1/ko not_active Expired - Fee Related
- 2009-10-01 WO PCT/EP2009/062787 patent/WO2010037831A1/en not_active Ceased
- 2009-10-01 SI SI200931016T patent/SI2342233T1/sl unknown
- 2009-10-01 NZ NZ592363A patent/NZ592363A/xx not_active IP Right Cessation
- 2009-10-01 RU RU2011115559/10A patent/RU2573897C2/ru not_active IP Right Cessation
- 2009-10-01 MA MA33784A patent/MA32928B1/fr unknown
- 2009-10-01 EP EP09744645.4A patent/EP2342233B1/en active Active
-
2010
- 2010-03-30 US US12/749,891 patent/US8557964B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 IL IL212066A patent/IL212066A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000730A patent/CL2011000730A1/es unknown
- 2011-04-20 ZA ZA2011/02969A patent/ZA201102969B/en unknown
- 2011-06-23 US US13/167,329 patent/US20110287451A1/en not_active Abandoned
- 2011-06-23 US US13/167,321 patent/US20110294156A1/en not_active Abandoned
-
2013
- 2013-09-13 US US14/025,875 patent/US9388248B2/en not_active Expired - Fee Related
-
2014
- 2014-09-24 CY CY20141100778T patent/CY1115572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073748A1 (es) | Anticuerpos anti-cxcr4 y su utilizacion para el tratamiento del cancer | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| CY1116584T1 (el) | Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης | |
| CO6571881A2 (es) | Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer | |
| ATE505489T1 (de) | Tgf-beta-1-spezifische antikörper | |
| UY32917A (es) | Moléculas de unión a dll-4 | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| CY1119696T1 (el) | Cc-1065 αναλογα και τα συζευγματα αυτων | |
| CY1117942T1 (el) | Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april) | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| AR073072A1 (es) | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano | |
| CY1113309T1 (el) | Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα | |
| CY1113212T1 (el) | Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| EA201201533A1 (ru) | Prlr-специфическое антитело и его применения | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| CL2008001682A1 (es) | Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos. | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| NO20081883L (no) | Modulasjon av glukokortikoidreseptorekspresjon | |
| CL2008002153A1 (es) | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. | |
| CY1118835T1 (el) | Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει | |
| CL2008001517A1 (es) | Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga. | |
| BR112014026440A2 (pt) | assays, methods and apparatus for assessing rna disruption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |